We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
Read MoreHide Full Article
Key Takeaways
Insmed posted preliminary FY25 revenues of $606.4M, topping forecasts on Arikayce and Brinsupri sales.
Brinsupri delivered $172.7M in 2025 sales, with $144.6M generated in Q4, its first full launch quarter.
Outlines 2026 plans, including Arikayce guidance, ENCORE data timing and multiple phase III TPIP studies.
Shares of Insmed (INSM - Free Report) gained more than 3% on Friday after the company reported preliminary sales numbers for full-year 2025. It also outlined some expected milestones related to its commercial portfolio and pipeline candidates for 2026.
Insmed’s FY25 Preliminary Sales Exceed Forecasts
The company reported unaudited/preliminary revenues of $606.4 million, which beat the Zacks Consensus Estimate of $509.5 million. Per Insmed, this reported figure was generated entirely from the sales of its two marketed drugs, Arikayce and Brinsupri.
While Arikayce is approved to treat refractory mycobacterium avium complex (MAC) lung disease in adults with limited or no treatment options, Brinsupri was approved last year as the first FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB).
Insmed reported preliminary product sales of Arikayce to be around $433.8 million for full-year 2025, up 19% year over year, driven by continued growth in demand across all marketed regions. This figure also exceeded its previously issued guidance of $420-$430 million.
However, the highlight of these results was the reported Brinsupri sales for the full year, which Insmed claims were $172.7 million. This was encouraging uptake for a drug that was approved in August. Per the company, the drug generated $144.6 million in the fourth quarter of 2025 — the first full quarter of its product launch. Brinsupri had previously generated $28.1 million from the drug’s sales in the third quarter.
INSM Stock Performance
Several investors and Wall Street analysts expressed optimism around the preliminary sales numbers for Brinsupri, which exceeded expectations. Some investors even pointed out that the drug could achieve blockbuster status as early as this year, if sales continue to grow at a phenomenal pace.
In the past year, shares of Insmed have skyrocketed 155% compared with the industry’s 20% growth.
Image Source: Zacks Investment Research
INSM's 2026 Expected Milestones and Pipeline Goals
Alongside the preliminary numbers, Insmed issued fresh financial guidance for 2026. It expects product sales from Arikayce to be between $450 million and $470 million, indicating 6% year-over-year growth at the midpoint compared to the preliminary sales figure for 2025.
The company also provided updates on its pipeline.
Insmed has already completed enrolling patients in the confirmatory phase III ENCORE study, which is evaluating Arikayce as a potential treatment for newly infected patients with MAC lung disease. Top-line data from this study is expected in March or April. If the data is positive, INSM plans to submit a regulatory filing for the drug with the FDA in the second half of 2026.
Apart from bronchiectasis, Insmed is evaluating Brinsupri in the phase IIb CEDAR study for the hidradenitis suppurativa indication. Top-line data from the study is expected in the second quarter of 2026.
Insmed is also progressing well with the late-stage development plans for its investigational treprostinil palmitil inhalation powder (TPIP). During the fourth quarter of 2025, it started the phase III PALM-ILD study evaluating the therapy in pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication. The company is also on track to start separate late-stage studies on TPIP across pulmonary arterial hypertension (PAH), progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) indications this year. While the PAH study is planned to start in early 2026, the PPF and IPF studies are expected to start in the second half of the year.
Insmed is also enrolling patients in cohorts 2 and 3 of the phase I ASCEND study evaluating its lead gene therapy, INS2101, for Duchenne muscular dystrophy. The company is also moving toward advancing INS1202, its gene therapy candidate for ALS patients, in a clinical study soon.
Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88.
CorMedix’s earnings beat estimates in the trailing four quarters, delivering an average surprise of 27.04%.
In the past 60 days, estimates for Keros Therapeutics’ 2025 earnings per share (EPS) have risen from $2.02 to $2.25. Loss estimates for 2026 have improved from $3.65 to $3.47 during the same period. In the past year, shares of KROS have risen 50%.
KROS’s earnings beat estimates in three of the trailing four quarters, while missing the mark on one occasion. On average, the company delivered a surprise of 9,098.63%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced
Key Takeaways
Shares of Insmed (INSM - Free Report) gained more than 3% on Friday after the company reported preliminary sales numbers for full-year 2025. It also outlined some expected milestones related to its commercial portfolio and pipeline candidates for 2026.
Insmed’s FY25 Preliminary Sales Exceed Forecasts
The company reported unaudited/preliminary revenues of $606.4 million, which beat the Zacks Consensus Estimate of $509.5 million. Per Insmed, this reported figure was generated entirely from the sales of its two marketed drugs, Arikayce and Brinsupri.
While Arikayce is approved to treat refractory mycobacterium avium complex (MAC) lung disease in adults with limited or no treatment options, Brinsupri was approved last year as the first FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB).
Insmed reported preliminary product sales of Arikayce to be around $433.8 million for full-year 2025, up 19% year over year, driven by continued growth in demand across all marketed regions. This figure also exceeded its previously issued guidance of $420-$430 million.
However, the highlight of these results was the reported Brinsupri sales for the full year, which Insmed claims were $172.7 million. This was encouraging uptake for a drug that was approved in August. Per the company, the drug generated $144.6 million in the fourth quarter of 2025 — the first full quarter of its product launch. Brinsupri had previously generated $28.1 million from the drug’s sales in the third quarter.
INSM Stock Performance
Several investors and Wall Street analysts expressed optimism around the preliminary sales numbers for Brinsupri, which exceeded expectations. Some investors even pointed out that the drug could achieve blockbuster status as early as this year, if sales continue to grow at a phenomenal pace.
In the past year, shares of Insmed have skyrocketed 155% compared with the industry’s 20% growth.
Image Source: Zacks Investment Research
INSM's 2026 Expected Milestones and Pipeline Goals
Alongside the preliminary numbers, Insmed issued fresh financial guidance for 2026. It expects product sales from Arikayce to be between $450 million and $470 million, indicating 6% year-over-year growth at the midpoint compared to the preliminary sales figure for 2025.
The company also provided updates on its pipeline.
Insmed has already completed enrolling patients in the confirmatory phase III ENCORE study, which is evaluating Arikayce as a potential treatment for newly infected patients with MAC lung disease. Top-line data from this study is expected in March or April. If the data is positive, INSM plans to submit a regulatory filing for the drug with the FDA in the second half of 2026.
Apart from bronchiectasis, Insmed is evaluating Brinsupri in the phase IIb CEDAR study for the hidradenitis suppurativa indication. Top-line data from the study is expected in the second quarter of 2026.
Insmed is also progressing well with the late-stage development plans for its investigational treprostinil palmitil inhalation powder (TPIP). During the fourth quarter of 2025, it started the phase III PALM-ILD study evaluating the therapy in pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication. The company is also on track to start separate late-stage studies on TPIP across pulmonary arterial hypertension (PAH), progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) indications this year. While the PAH study is planned to start in early 2026, the PPF and IPF studies are expected to start in the second half of the year.
Insmed is also enrolling patients in cohorts 2 and 3 of the phase I ASCEND study evaluating its lead gene therapy, INS2101, for Duchenne muscular dystrophy. The company is also moving toward advancing INS1202, its gene therapy candidate for ALS patients, in a clinical study soon.
INSM’s Zacks Rank
Insmed currently carries a Zacks Rank #3 (Hold).
Insmed, Inc. Price
Insmed, Inc. price | Insmed, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are CorMedix (CRMD - Free Report) and Keros Therapeutics (KROS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88.
CorMedix’s earnings beat estimates in the trailing four quarters, delivering an average surprise of 27.04%.
In the past 60 days, estimates for Keros Therapeutics’ 2025 earnings per share (EPS) have risen from $2.02 to $2.25. Loss estimates for 2026 have improved from $3.65 to $3.47 during the same period. In the past year, shares of KROS have risen 50%.
KROS’s earnings beat estimates in three of the trailing four quarters, while missing the mark on one occasion. On average, the company delivered a surprise of 9,098.63%.